Skip to Main content Skip to Navigation
Journal articles

Cerebrospinal fluid Alzheimer biomarkers can be useful for discriminating dementia with Lewy bodies from Alzheimer’s disease at the prodromal stage

Abstract : Background Differential diagnosis between dementia with Lewy bodies (DLB) and Alzheimer’s disease (AD) is not straightforward, especially in the early stages of disease. We compared AD biomarkers (phospho-Tau 181 , total-Tau, Aβ42 and Aβ40) in cerebrospinal fluid (CSF) of patients with DLB and AD, focusing especially on the prodromal stage. Methods A total of 1221 CSF were collected in different memory centres (ePLM network) in France and analysed retrospectively. Samples were obtained from patients with prodromal DLB (pro-DLB; n=57), DLB dementia (DLB-d; n=154), prodromal AD (pro-AD; n=132) and AD dementia (n=783), and control subjects (CS; n=95). These centres use the same diagnostic procedure and criteria to evaluate the patients. Results In patients with pro-DLB, CSF Aβ42 levels appeared much less disrupted than in patients at the demented stage (DLB-d) (P<0.05 CS>pro-DLB; P<0.001 CS>DLB-d). On average, Aβ40 levels in patients with DLB (pro-DLB and DLB-d) were much below those in patients with pro-AD (P<0.001 DLB groups
Document type :
Journal articles
Complete list of metadata

https://hal-univ-fcomte.archives-ouvertes.fr/hal-03630167
Contributor : Eloi Magnin Connect in order to contact the contributor
Submitted on : Monday, April 4, 2022 - 6:30:32 PM
Last modification on : Monday, April 4, 2022 - 6:30:33 PM

Identifiers

Collections

Citation

Olivier Bousiges, Stephanie Bombois, Susanna Schraen, David Wallon, Muriel Muraine Quillard, et al.. Cerebrospinal fluid Alzheimer biomarkers can be useful for discriminating dementia with Lewy bodies from Alzheimer’s disease at the prodromal stage. Journal of Neurology, Neurosurgery and Psychiatry, BMJ Publishing Group, 2018, 89 (5), pp.467-475. ⟨10.1136/jnnp-2017-316385⟩. ⟨hal-03630167⟩

Share

Metrics

Record views

5